USANA Health Sciences, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Common Stock and Earnings Per Share

Common Stock and Earnings Per Share

12 Months Ended

Dec. 30, 2023

COMMON STOCK AND EARNINGS PER SHARE

Basic earnings per share (“EPS”) are based on the weighted-average number of shares outstanding for each period. Shares that have been repurchased and retired during the periods specified below have been included in the calculation of the number of weighted-average shares that are outstanding for the calculation of basic EPS based on the time they were outstanding in any period. Diluted EPS are based on shares that are outstanding (computed under basic EPS) and on potentially dilutive shares. Shares that are included in the diluted EPS calculations under the treasury stock method include equity awards that are in-the-money but have not yet been exercised.

The following is a reconciliation of the numerator and denominator used to calculate basic EPS and diluted EPS for the periods indicated:


	Year Ended
	2023		2022		2021
Net earnings available to common shareholders	$	63,788	$	69,350	$	116,505
Weighted average common shares outstanding - basic	19,250		19,254		20,146
Dilutive effect of in-the-money equity awards	95		56		197
Weighted average common shares outstanding - diluted	19,345		19,310		20,343
Earnings per common share from net earnings - basic	$	3.31	$	3.60	$	5.78
Earnings per common share from net earnings - diluted	$	3.30	$	3.59	$	5.73

Equity awards for the following shares were not included in the computation of diluted EPS due to the fact that their effect would be anti-dilutive:


Year Ended
2023	2022	2021
319	354	60

During the year ended 2023, the Company repurchased and retired 180 shares for $11,653 including accrued excise tax of $54. During the years ended 2022 and 2021, the Company repurchased and retired 288 shares, and 1,844 shares for an aggregate price of $25,382 and $177,837, respectively.